Administration of Subcutaneous Teicoplanin in the Treatment of Osteoarticular Infections: Tolerance Study

• Status: Completed
• Trial end date: 2015-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a biomedical research, prospective, mono centric, tolerance study Of the administration of subcutaneous teicoplanin in the treatment of osteoarticular infections.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier Universitaire, Amiens
• Treatments: Teicoplanin

Criteria

Inclusion Criteria:

• Patient over 18 years

• Inpatient orthopedic surgery

• Achieved a bone and joint infection documented gram + (staphylococci golden coagulase-negative staphylococci, enterococci, streptococci)

• Bacteria resistant to lincosamides, quinolones and rifampicin

• Bacteria susceptible to teicoplanin (MIC ≤ 4 mg / L)

• Balanced patient teicoplanin administered intravenously (2 successive doses between 30 and 40 mg / mL)

Exclusion Criteria:

• Patient not affiliated to the social security

• Pregnant and lactating women

• Known hypersensitivity to teicoplanin (rash, ...)

• Patients with a central catheter or an implantable chamber

• Patient hemodialysis

• Patient has another participant biomedical research on a drug to prevent drug interactions

• Patient minor

• Patient major protected (protection of the court, wardship, trusteeship)

• Patient admitted for emergency or incapable of consent